The Protective Effect of Selenium Nanoparticles in Osteoarthritis: In vitro and in vivo Studies
Yong Li,Senbo Zhu,Junchao Luo,Yu Tong,Yixuan Zheng,Lichen Ji,Zeju He,Qiangan Jing,Jiaqing Huang,Yinjun Zhang,Qing Bi
DOI: https://doi.org/10.2147/dddt.s407122
2023-05-22
Abstract:Yong Li, 1, 2, &ast Senbo Zhu, 2, &ast Junchao Luo, 2 Yu Tong, 2 Yixuan Zheng, 1 Lichen Ji, 2 Zeju He, 2 Qiangan Jing, 1 Jiaqing Huang, 2 Yinjun Zhang, 1 Qing Bi 2 1 College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, People's Republic of China; 2 Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yinjun Zhang, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, People's Republic of China, Tel +86-13735494556, Email Qing Bi, Laboratory Medicine Center, Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People's Republic of China, Tel +86-13588302991, Email Introduction: Osteoarthritis (OA) is a common chronic joint disease characterized by articular cartilage degeneration. OA usually manifests as joint pain, limited mobility, and joint effusion. Currently, the primary OA treatment is non-steroidal anti-inflammatory drugs (NSAIDs). Although they can alleviate the disease's clinical symptoms and signs, the drugs have some side effects. Selenium nanoparticles (SeNPs) may be an alternative to relieve OA symptoms. Materials and Results: We confirmed the anti-inflammatory effect of selenium nanoparticles (SeNPs) in vitro and in vivo experiments for OA disease in this study. In vitro experiments, we found that SeNPs could significantly reduce the expression of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), the major inflammatory factors, and had significant anti-inflammatory and anti-arthritic effects. SeNPs can inhibit reactive oxygen species (ROS) production and increased glutathione peroxidase (GPx) activity in interleukin-1beta (IL-1β)-stimulated cells. Additionally, SeNPs down-regulated matrix metalloproteinase-13 (MMP-13) and thrombospondin motifs 5 (ADAMTS-5) expressions, while up-regulated type II collagen (COL-2) and aggrecan (ACAN) expressions stimulated by IL-1β. The findings also indicated that SeNPs may exert their effects through suppressing the NF-κB p65 and p38/MAPK pathways. In vivo experiments, the prevention of OA development brought on by SeNPs was demonstrated using a DMM model. Discussion: Our results suggest that SeNPs may be a potential anti-inflammatory agent for treating OA. Keywords: osteoarthritis, NF-κB p65 signaling pathway, p38/MAPK signaling pathway, selenium nanoparticles Osteoarthritis (OA) is a prevalent chronic degenerative joint disease that is more common in middle-aged and elderly people. 1 Its primary characteristics are subchondral sclerosis, joint swelling, synovitis, and gradual loss of articular cartilage. 2 The clinical manifestations of OA are slow joint pain, tenderness, stiffness, joint swelling, limited mobility, and joint deformity, which seriously hinders work and affects human life quality. 3,4 Inflammation and catabolism are closely related to the occurrence and development of OA. 5 The potential pathogenesis of OA is still elusive. 6 Articular cartilage degradation is primarily associated with the protein overproduction that breaks down cartilage, including matrix metalloproteinases (MMPs), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), and other catabolic enzymes. 7 Inflammatory factors, such as IL-1β, play a vital role in bone and joint damage and inflammation. 8 The production of ADAMTS and MMPs can be increased by IL-1β, stimulating extracellular matrix (ECM) degradation, and decreasing aggrecan (ACAN) and type II collagen (COL-2) synthesis. 9,10 Meanwhile, IL-1β can induce the release of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), which can create nitric oxide (NO) and prostaglandin E2 (PGE2). 11 IL-1β can induce inflammatory cytokines interleukin (IL)-6 and NO expressions with excessive reactive oxygen species (ROS) production. 12 ROS or free radicals cause oxidative stress, the primary pathophysiology of OA. 13 Increasing evidence suggests that neutralizing IL-1β-induced inflammatory mediators may help to treat OA. 14 Patients with advanced OA are treated with total knee replacement, whereas patients with mild disease are mostly treated with nonsteroidal anti-inflammatory drugs (NSAIDs).<sup -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal